Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use XPOVIO safely and effectively. See full prescribing information for XPOVIO. XPOVIO® (selinexor) tablets, for oral useInitial U.S. Approval: 2019
Medication labelWhy this: Advisory · dailymed-prescription
XPOVIO in combination with bortezomib and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. XPOVIO in combination with dexamethasone is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.
- generic_name
- selinexor
- product_names
- selinexor
- ndc
- 72237-106, 72237-106-11, 72237-106-01, 72237-101, 72237-101-13, 72237-101-03, 72237-101-14, 72237-101-04, 72237-102, 72237-102-17, 72237-102-07, 72237-102-16, 72237-102-06, 72237-102-12, 72237-102-02, 72237-103, 72237-103-15, 72237-103-05, 72237-104, 72237-104-11, 72237-104-01, 72237-105, 72237-105-11, 72237-105-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en